VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to support development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA's BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.
By integrating artificial intelligence into its research and development strategy, VERAXA aims to enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates.
According to the press release, VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by transformative technologies and guided by quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL).
For more information, view the full press release at https://ibn.fm/GLFg2. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
This collaboration comes as AI continues to transform drug discovery, offering the potential to analyze vast datasets and identify novel targets more efficiently than traditional methods. For VERAXA, the partnership could accelerate the development of its BiTAC platform, which aims to engage T cells to attack tumors while minimizing damage to healthy tissue. The implications are significant: if successful, this AI-driven approach could lead to more effective cancer therapies with fewer side effects, addressing a critical need in oncology.
Forward-looking statements in this article involve risks and uncertainties, including factors beyond management's control. These are detailed in the company's SEC filings, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Undue reliance should not be placed on forward-looking statements, and the company undertakes no duty to update this information unless required by law.
